Luis Rico | Oncology | Editorial Board Member

Published on by Oncology

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Shahanavaj Khan | Cancer Science | Editorial Board Member

Published on by Oncology

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.

George Kroumpouzos | Skin Oncology | Editorial Board Member

Published on by Oncology

Prof. Dr. George Kroumpouzos | Skin Oncology | Editorial Board Member

Professor | Jundiai Medical School, Brazil / Alpert Medical School of Brown University, USA |  United States

Dr. George Kroumpouzos is an internationally recognized dermatologist affiliated with The Warren Alpert Medical School of Brown University, United States, known for his extensive contributions to medical, surgical, cosmetic, and psychocutaneous dermatology, with a strong recent focus on the integration of artificial intelligence, large language models, and virtual reality into diagnostic and therapeutic practices. He has authored 162 peer-reviewed publications, covering clinically significant topics such as counterfeit botulinum toxin and cosmetic iatrogenic botulism, Er:YAG laser therapy for vulvovaginal atrophy in breast cancer survivors, exosome-based treatments for pattern hair loss, AI-driven innovations in maternal–fetal dermatology, and advanced nonsurgical rhinoplasty techniques. His broad collaborative network spanning more than 200 researchers globally highlights his commitment to interdisciplinary advancement across dermatology, aesthetic medicine, oncology, psychology, and women’s health. Dr. Kroumpouzos’s scholarly work consistently promotes patient safety, diagnostic accuracy, and equitable access to cutting-edge dermatologic care, positioning him as a leading voice in regulatory reform and digital transformation within the field. His global impact is underscored by his ability to bridge clinical insight with emerging technologies, shaping future standards and addressing diverse patient needs across populations. Dr. Kroumpouzos’s academic influence and research productivity are reflected in his metrics: 2,695 citations, 162 documents, and an h-index of 28.

profiles: Scopus| ORCID | ResearchGate

Featured Publications

Türk, C. B., Mirza, F. N., & Kroumpouzos, G. (2023). A screening proposal for Zoom dysmorphia in virtual settings. Life, 13(8), Article 1678.

Bhargava, S., Yumeen, S., Henebeng, E., & Kroumpouzos, G. (2022). Erosive pustular dermatosis: Delving into etiopathogenesis and management. Life, 12(12), Article 2097.

Kroumpouzos, G., Paroikaki, M. E., Yumeen, S., Bhargava, S., & Mylonakis, E. (2022). Cutaneous complications of mRNA and AZD1222 COVID-19 vaccines: A worldwide review. Microorganisms, 10(3), Article 624.

Das, K., Daveluy, S., Kroumpouzos, G., Agarwal, K., Podder, I., Farnbach, K., Ortega-Loayza, A. G., Szepietowski, J. C., Grabbe, S., & Goldust, M. (2022). Efficacy and toxicity of classical immunosuppressants, retinoids and biologics in hidradenitis suppurativa. Journal of Clinical Medicine, 11(3), Article 670.

Messas, T., Messas, A., & Kroumpouzos, G. (2021). Carbon dioxide laser vulvovaginal rejuvenation: A systematic review. Cosmetics, 8(3), Article 56.

Omar Alqaisi | Skin Cancer | Best Researcher Award

Published on by Oncology

Mr. Omar Alqaisi | Skin Cancer | Best Researcher Award

Al-Zaytoonah University of Jordan | Jordan

Dr. Omar M. Alqaisi is a dedicated academic and researcher at Al-Zaytoonah University of Jordan whose scholarly contributions reflect a strong commitment to advancing healthcare through evidence-based nursing practice and oncology research. With 11 published documents, 46 citations, and an h-index of 3, his work demonstrates a consistent trajectory of academic growth and increasing impact in the fields of clinical nursing, psycho-oncology, and patient-centered care. His notable publication, “A Narrative Review of the Roles of Nursing in Addressing Sexual Dysfunction in Oncology Patients,” underscores his focus on addressing sensitive and underexplored areas of oncology, particularly the psychosocial and emotional well-being of cancer patients, while emphasizing the indispensable role of nurses in holistic recovery and improving quality of life. A hallmark of his career is his emphasis on interdisciplinary collaboration, evidenced by co-authorship with more than 100 researchers across multiple disciplines, reflecting his ability to foster teamwork and integrate diverse perspectives to address complex healthcare challenges. His research is characterized by analytical precision, ethical grounding, and a human-centered approach, aligning with global healthcare trends that prioritize compassion, inclusivity, and evidence-based interventions. Beyond individual studies, Dr. Alqaisi’s work contributes to the broader advancement of nursing education, clinical practice, and patient advocacy in oncology. His growing academic influence positions him as an emerging leader within regional and international research communities. With continued development in empirical methodologies, digital health innovations, and cross-cultural healthcare models, he is poised to expand his contributions to global nursing and oncology discourse. Dr. Alqaisi’s research not only advances academic understanding but also creates meaningful societal impact by emphasizing empathy, communication, and the integration of psychosocial care into clinical frameworks, exemplifying a new generation of scholars committed to bridging scientific innovation with humanistic healthcare practice.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

1. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, October 9). Immune checkpoint inhibitors in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Cancers, 17(19), 3272.

2. Alqaisi, O., Al-Ghabeesh, S., Tai, P., Wong, K., Joseph, K., & Yu, E. (2025, August 14). A narrative review of the roles of nursing in addressing sexual dysfunction in oncology patients. Current Oncology, 32(8), 457.

3. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, July 25). Immunotherapy in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Preprints, 202507.2063.v1.

4. Alqaisi, O., Subih, M., Joseph, K., Yu, E., & Tai, P. (2025, June). Oncology nurses’ attitudes, knowledge, and practices in providing sexuality care to cancer patients: A scoping review. Current Oncology, 32(6), 337.

5. Alqaisi, O. M., & Al-Ghabeesh, S. (2024, July 31). Quality of postoperative pain management in orthopedic patients and its impact on sleep quality and patient satisfaction: An integrative review. Cureus, 16(7), e65872.

Dr. Omar M. Alqaisi’s research advances the integration of compassionate, evidence-based nursing within oncology care, addressing both clinical and psychosocial patient needs. His work strengthens global healthcare practices by promoting interdisciplinary collaboration, enhancing patient quality of life, and shaping innovative models for holistic, human-centered medical care.

Excellence in Translational Medicine in Oncology Award

Published on by Oncology

Introduction: Welcome to the pinnacle of innovation in healthcare! The Excellence in Translational Medicine in Oncology Award is a beacon for those pushing the boundaries of research and clinical application in the fight against cancer. Join us in recognizing and celebrating the visionaries shaping the future of translational medicine.

Award Eligibility: Open to global medical professionals and researchers, this award has no age limits. To qualify, candidates must hold a doctoral degree, showcase significant contributions to translational medicine in oncology, and have a noteworthy publication record in reputable journals.

Evaluation Criteria: Candidates will be evaluated on the transformative impact of their translational research, the quality and relevance of publications, and their contributions to bridging the gap between laboratory discoveries and clinical applications in oncology.

Submission Guidelines: Entrants must submit a comprehensive package including a detailed biography, an abstract of their translational research, and supporting files. Adherence to specified format guidelines is crucial for a fair evaluation process.

Recognition and Community Impact: The award not only honors individual excellence but also acknowledges the broader impact of the recipient's work on the oncology community and patient care. Awardees will be recognized at prominent events, amplifying the reach and influence of their translational endeavors.